Drug identified that could limit the spread of deadly brain tumors
News Nov 13, 2015
Study shows PPF could help treat glioblastomas by sensitizing tumors to chemotherapy and radiation treatments -
In a significant breakthrough, the Translational Genomics Research Institute (TGen) has identified a drug, propentofylline or PPF, that could help treat patients with deadly brain cancer.
In a study published in the Journal of NeuroOncology, TGen researchers report that PPF works to limit the spread of glioblastoma multiforme, or GBM—the most common primary tumor of the brain and central nervous system—by targeting a protein called TROY.
In addition, TGen laboratory research also found that PPF increases the effectiveness of a standard-of-care chemotherapy drug called temozolomide (TMZ), and radiation, to treat glioblastoma.
"We showed that PPF decreased glioblastoma cell expression of TROY, inhibited glioma cell invasion, and made brain cancer cells more vulnerable to TMZ and radiation," said Dr. Nhan Tran, Associate Professor and head of TGen's Central Nervous System Tumor Research Lab.
An advantage of small-molecule PPF—which has been previously used in clinical trials in an attempt to treat Alzheimer's disease and dementia—is that it can penetrate the blood-brain barrier and reach the tumor. And, the FDA has already approved it.
"Our data suggests that PPF, working in combination with TMZ and radiation, could limit glioblastoma invasion and improve the clinical outcome for brain tumor patients," said Dr. Tran, the study's senior author.
"GBM is one of the most aggressive of all cancers and it affects people of all ages," said Catherine (Bracken) Ivy, founder and president of The Ben & Catherine Ivy Foundation. "Funding research focused on helping patients survive longer is critical, and studies such as this advance our goal of not only improving treatments for brain cancer, but eventually finding a cure."
One of the primary treatments for glioblastoma is surgical removal of the tumor. However, because of the aggressive way glioblastomas invade surrounding brain tissue, it is impossible to remove all parts of the tumors, and the cancer eventually returns and spreads. This insidious cancer invasion also limits the effectiveness of chemotherapy drugs and radiation therapy.
TGen found that PPF works to limit the spread of glioblastomas by targeting and knocking down the expression of the TROY protein. TGen researchers have linked TROY to the cellular mechanisms that enable glioblastomas to invade normal brain cells, and resist anti-cancer drugs.
"New therapeutic strategies that target the molecular drivers of invasion are required for improved clinical outcome," said Dr. Harshil Dhruv, a TGen Research Assistant Professor and lead author of the study. "Propentofylline may provide a pharmacologic approach to targeting TROY, inhibiting cell invasion and reducing therapeutic resistance in glioblastomas."
One of the fundamental challenges in treating brain cancer with drugs is what is known as the blood-brain barrier that separates circulating blood from the brain extracellular fluid in the central nervous system. This barrier works to protect the brain from toxins. However, this security system is so effective at protecting the brain that it prevents many life-saving drugs -- all but some small molecules -- from being able to treat cancer and other diseases of the brain.
As a result, there has been little progress in recent decades in finding new effective treatments for GBM. Median survival for newly diagnosed GBM patients is only 14.6 months. Only 5 percent of patients survive more than 5 years.
"Clinical trials revealed that PPF can cross the blood-brain barrier, and has minimal side effects," Dr. Tran said. "PPF could be easily translated to the clinic as an adjuvant therapy in combination with standard of care treatment for GBM patients."
Note: Material may have been edited for length and content. For further information, please contact the cited source.
Dhruv HD et al. Propentofylline inhibits glioblastoma cell invasion and survival by targeting the TROY signaling pathway. Journal of Neuro-Oncology, Published Online November 12 2015. doi: 10.1007/s11060-015-1981-0
Through the Eyes of the Crab: Binocular processing of object motion in the crustaceanNews
The widely spaced eyes and visually guided behaviors of the crab Neohelice granulata suggest it may compute visual parameters of moving targets by combining input from both eyes.READ MORE
Perinatal Exposure to Phthalates Results in Lower Number of Neurons and Synapses in the Medial Prefrontal CortexNews
Phthalates - chemicals used in plastics belonging to the same class as Bisphenol A (BPA) - can potentially interfere with hormones important for the developing brain.READ MORE
Key Social Reward Circuit in the Brain Impaired in Kids With AutismNews
Deficits in the brain’s reward circuit are linked to social deficits in children with autism and may point the way toward better treatments, according to a new Stanford study.READ MORE